Market-by-Market Whitening Concentration Checklists

Map whitening concentration limits by market — EU, US, UK, AU, Canada, GCC — with concentration thresholds, labeling triggers, and pre-sale documentation requirements.

Whitening Concentration Limits by Market: A Compliance Checklist for Distributors and Private-Label Buyers

For distributors and private-label buyers sourcing across multiple regions, whitening concentration limits by market are not a background compliance detail — they are the variable that determines whether a shipment clears customs or gets held. A strip formulated at a given hydrogen peroxide concentration that sells legally through retail in one jurisdiction may be classified as a prescription-only medical device in another. Same SKU. Entirely different regulatory outcome.

Regulators across markets classify peroxide-based whitening products under different legal frameworks: cosmetics, over-the-counter drugs, medical devices, or dental therapeutics. Each classification carries its own concentration ceiling, labeling mandate, and pre-market documentation requirement. Distributors who treat this as a supplier problem rather than a sourcing strategy problem consistently encounter delays, rejections, and reformulation costs after purchase orders are committed.

This guide maps the thresholds, triggers, and documentation requirements for the markets your whitening SKUs are most likely to enter.

US Market: OTC Thresholds and Label Requirements

In the United States, the distinction between OTC and professional-use whitening products has direct sourcing consequences. The American Dental Association notes that OTC whitening products — strips, gels, and toothpastes sold without a prescription — generally use lower concentrations of hydrogen peroxide or carbamide peroxide than dentist-prescribed or in-office treatments, where licensed professionals work with substantially higher concentrations.

A product formulated for professional dispensing cannot be relabeled and sold through retail or direct-to-consumer channels without reformulation and reclassification. The FDA's OTC Drug Monograph framework governs whitening products that make drug claims — specifically, any claim that a product changes the color of tooth structure. Products under this framework must comply with active ingredient specifications, labeling language, and directions of use as defined in the applicable monograph.

Key label requirements for US OTC whitening products include:

Active ingredient declaration with concentration stated as a percentage
Directions specifying application time and frequency
Warnings addressing sensitivity and age restrictions (generally not for use under 12)
Net quantity and manufacturer or distributor contact information

Private-label buyers co-developing a whitening strip or gel for the US market need to confirm at the formulation stage — not the packaging stage — that the active ingredient concentration sits within OTC-compliant limits. Reformulating after label artwork is finalized is a preventable cost.

EU Market: Whitening Concentration Limits by Market Tier and Responsible Person Obligations

The European Union regulates tooth whitening products containing hydrogen peroxide under Annex III of the EU Cosmetics Regulation (EC) No 1223/2009. This regulation sets explicit concentration caps that determine both a product's legal status and who may supply it to the end user.

The EU framework creates a tiered access structure based on peroxide concentration. Products above the consumer-access threshold may only be sold to or through dental professionals for the first cycle of use, after which the professional may supply the consumer with subsequent applications. For distributors placing product into EU retail or pharmacy channels, a formulation above the consumer threshold is not legally available for direct-to-consumer sale regardless of how it is labeled or marketed.

Every cosmetic product placed on the EU market also requires a Responsible Person (RP) established within the EU. The RP holds the Product Information File (PIF), which must include:

A Cosmetic Product Safety Report (CPSR) signed by a qualified safety assessor
A description of the manufacturing method and a GMP compliance statement
Evidence supporting any efficacy claims made on the label or in marketing
Ingredient listing compliant with INCI nomenclature

Distributors importing whitening products into the EU without a designated RP in place are placing product on the market illegally — regardless of whether the formulation itself is concentration-compliant. This is a structural requirement, not a paperwork formality.

UK Post-Brexit Rules: Where Requirements Diverge and What Buyers Must Re-file

Since the UK's departure from the EU single market, Great Britain operates its own cosmetics regulatory framework under the UK Cosmetics Regulation — broadly retained from the EU regulation but administered separately. Northern Ireland retains alignment with EU rules under the Windsor Framework, creating a split compliance requirement for any distributor supplying the whole of the UK.

The divergence points that carry the most operational weight for whitening buyers:

Responsible Person: A UK RP must be established separately from any EU RP. An EU-based RP does not satisfy Great Britain requirements.
Product notification: Products must be notified through the UK's Cosmetic Product Notification Portal, not the EU CPNP.
Labeling: A UK address for the RP must appear on the label. EU-addressed labels are not compliant for Great Britain market placement.
Northern Ireland: Products entering Northern Ireland may require dual compliance — UK and EU — depending on the supply chain route.

Buyers who built their EU compliance package before 2021 and have not re-filed for the UK are operating on expired assumptions. This is one of the most common documentation gaps among distributors who entered the EU market pre-Brexit.

Canada, Australia, and GCC: Secondary Markets With Primary-Level Complexity

These three markets are frequently treated as extensions of US or EU compliance frameworks. They are not. Each has distinct whitening concentration limits by market and distinct pre-market requirements that can block import if overlooked at the sourcing stage.

Canada

Health Canada classifies peroxide-containing whitening products as either cosmetics or drugs depending on concentration and the claims made. Products making therapeutic claims — including claims about treating tooth discoloration as a condition — are regulated as drugs and require a Drug Identification Number (DIN) or Natural Product Number (NPN) before sale. Cosmetic products must be notified to Health Canada within 10 days of first sale in Canada. Distributors sourcing whitening strips or gels for the Canadian market need to confirm classification at both the formulation level and the claims level before committing to a SKU.

Australia

Australia's regulatory environment for whitening products is among the most prescriptive globally for non-dental-professional access. The Australian Dental Association's policy identifies hydrogen peroxide concentrations in the range of approximately 3–6% as associated with some home-use products, concentrations up to 35% as used in professional in-office settings, and notes that 18% carbamide peroxide is approximately equivalent to 6% hydrogen peroxide. The Therapeutic Goods Administration (TGA) regulates whitening products containing peroxide above defined thresholds as therapeutic goods, requiring registration or listing on the Australian Register of Therapeutic Goods (ARTG) before import or sale. Products below the threshold may be regulated as cosmetics under a separate pathway. Importers must confirm which pathway applies before a shipment is arranged.

GCC (Gulf Cooperation Council)

The GCC Standardization Organization has adopted cosmetics regulations that draw from EU frameworks but are not identical to them. Saudi Arabia's SFDA and the UAE's ESMA each maintain national-level enforcement on top of the regional framework. Whitening products entering GCC markets typically require conformity certificates, Arabic-language labeling, and registration with the relevant national authority prior to customs clearance. Distributors entering this market for the first time consistently underestimate registration timelines — plan for several months, not weeks.

Documentation Every Supplier Must Provide Before You List or Distribute

Regardless of target market, there is a baseline documentation set that any supplier co-developing or supplying a whitening product for distribution should be expected to provide. Requesting this documentation before finalizing a sourcing agreement is standard practice — not an unusual ask.

Document	Why It Matters	Markets Where Required
Certificate of Analysis (CoA)	Confirms active ingredient concentration per batch	All markets
Safety Data Sheet (SDS)	Required for shipping classification and customs	All markets
Cosmetic Product Safety Report (CPSR)	Mandatory for EU and UK cosmetic classification	EU, UK
ISO 22716 GMP Certificate	Demonstrates manufacturing compliance	EU, UK, GCC, AU
Full Ingredient (INCI) Declaration	Required for labeling and regulatory notification	All markets
Stability Testing Data	Supports shelf-life claims and safety assessment	EU, UK, AU, CA
Efficacy or Clinical Data	Required when substantiating whitening claims	EU, UK, US (claim-dependent)

Clinical research confirms that concentration, application schedule, and treatment duration are each important factors in both whitening outcomes and tolerability. Efficacy documentation is not simply a regulatory checkbox — it is a defensible commercial asset when professional buyers are evaluating competing SKUs.

Building a Per-SKU Market-Entry Checklist

The most operationally sound approach for distributors managing multiple markets is a per-SKU compliance dossier that is built at formulation sign-off and updated at each market-entry stage. This dossier travels with the product — from development through customs clearance and onto the shelf or clinic dispensary.

A functional market-entry checklist for a whitening SKU addresses five layers:

Formulation classification: Confirm the active ingredient, concentration, and whether the product falls under cosmetic, OTC drug, or medical device classification in each target market.
Concentration compliance: Verify the formulation sits within the legal ceiling for each market. A single formulation may not satisfy all targets simultaneously — market-specific variants are sometimes the cleaner commercial decision.
Labeling compliance: Confirm mandatory language, warnings, RP or distributor address, and claim language for each market. A single master label rarely satisfies more than one or two markets without modification.
Pre-market registration or notification: Identify whether the product requires registration (AU, CA drug classification, GCC), notification (EU CPNP, UK portal, CA cosmetics), or monograph compliance (US OTC) — and build the timeline accordingly.
Ongoing batch documentation: CoA and SDS must be updated per production batch. A compliance dossier built on documentation from an earlier batch is not current compliance — it is a liability.

Private-label buyers co-developing products for multi-market distribution should confirm that their formulation partner can supply market-specific variants and the corresponding documentation set for each. A supplier that can formulate to a target concentration but cannot provide a signed CPSR or ISO 22716 certificate is not distribution-ready for regulated markets. WhiteningBright's private-label-ready whitening portfolio is engineered for exactly this kind of multi-market documentation transparency.

References

Disclaimer

This article is for general informational purposes only and does not constitute sourcing, legal, or regulatory advice. Always conduct your own due diligence and consult qualified legal or compliance professionals before making purchasing or compliance decisions. WhiteningBright makes no warranties as to the completeness or accuracy of the information, and any reliance is at your own risk.